ABVC BioPharma, Inc. (NASDAQ:ABVC - Get Free Report) was up 2.6% during mid-day trading on Monday . The company traded as high as $2.75 and last traded at $2.72. Approximately 58,424 shares traded hands during trading, a decline of 50% from the average daily volume of 116,636 shares. The stock had previously closed at $2.65.
ABVC BioPharma Stock Up 2.9%
The stock has a 50 day moving average of $3.11 and a 200 day moving average of $1.90. The firm has a market capitalization of $67.09 million, a price-to-earnings ratio of -16.76 and a beta of 0.27.
ABVC BioPharma (NASDAQ:ABVC - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.13) EPS for the quarter. ABVC BioPharma had a negative return on equity of 46.76% and a negative net margin of 963.46%.
Institutional Trading of ABVC BioPharma
An institutional investor recently raised its position in ABVC BioPharma stock. XTX Topco Ltd increased its stake in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Free Report) by 75.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,439 shares of the company's stock after acquiring an additional 26,034 shares during the period. XTX Topco Ltd owned about 0.36% of ABVC BioPharma worth $64,000 as of its most recent SEC filing. Institutional investors own 11.38% of the company's stock.
ABVC BioPharma Company Profile
(
Get Free Report)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
Featured Articles
Before you consider ABVC BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABVC BioPharma wasn't on the list.
While ABVC BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
